Mario Lemieux Immunotherapy Center
In November 2018, The Mario Lemieux Foundation further pledged their support for UPMC Hillman Cancer Center with a $5 million gift for groundbreaking on The Mario Lemieux Immunotherapy Center at UPMC Hillman Cancer Center. The Center has expanded and enhanced innovative immunotherapy treatments for patients with certain types of solid tumors through research and personalized patient care. It delivers the same level of innovative patient care for solid tumors as the Lemieux Center for Blood Cancers at UPMC Hillman affords blood cancer patients.
L-R: Tom Grealish, President of the Lemieux Board of Directors, Robert Ferris, M.D., Ph.D., director of UPMC Hillman Cancer Center, Mario Lemieux, Chairman of the Lemieux Board of Directors, and Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center
Immunotherapy is the treatment of a disease by using a person’s own immune cells. This novel treatment strengthens or regulates a person’s immune response faster and more efficiently than routine therapies and can enhance the body’s own defenses to fight cancer and other diseases.
Cancer experts at UPMC Hillman have been leaders in the field of immunotherapy for decades, successfully developing effective therapies for several cancers. In the recently launched UPMC Immune Transplant and Therapy Center, researchers are accelerating the pace at which medical teams are developing this next generation of care.
The Mario Lemieux Foundation Immunotherapy Center at UPMC Hillman Cancer Center, will be located on the second floor of UPMC Hillman Cancer Center. Just as the Lemieux Center for Blood Cancers at UPMC Hillman brought the latest discoveries and treatment options in a patient-centric environment, this new center for immunotherapy will bring the same level of care to patients with solid tumors.